Abbott Demonstrates End to End Laboratory Solutions

Abbott’s next-generation Alinity systems are taking center stage at ADLM 2024. The Alinity family is harmonized across key laboratory disciplines, streamlining critical interactions between individuals, systems, and information, and enabling labs to redefine performance. Abbott is demonstrating the Alinity ci-series of integrated clinical chemistry & immunoassay systems offering powerful integration across clinical chemistry and immunoassay. These systems can easily scale, combining up to four modules in multiple configurations to meet any laboratory's needs and maximize its operational efficiency. The Alinity c compact clinical chemistry system maximizes testing throughput with high-quality assays to deliver efficient and accurate performance. The Alinity I compact immunoassay system utilizes proven CHEMIFLEX chemiluminescent detection technology to provide greater confidence in results.

Abbott is also highlighting the Alinity h-series integrated hematology systems which deliver simplified workflows through an innovative design to streamline the hematology laboratory. The Alinity hq compact hematology system enables laboratories to run at maximum efficiency while the Alinity hs compact slidemaker stainer system for an automated workflow delivers consistency. Visitors to Abbott’s booth at ADLM 2024 can also experience the Alinity m fully integrated, automated, high-throughput molecular diagnostics analyzer with high-quality assays that delivers the next level of flexibility and efficiency to molecular labs. Also featuring at the show is Abbott’s award-winning i-STAT Alinity point-of-care system designed to be easy, accurate and connected, providing results in minutes and integrating diagnostic patient-testing directly into the clinical-care pathway.

Additionally, a Scientific Industry Workshop from Abbott led by an expert will focus on analytical and clinical aspects across high and low hs-cardiac troponin results, while covering factors that may lead to potential misdiagnosis of myocardial infarction. Abbott’s MED Talks and LAB Voice sessions will be 20-30 minute presentations covering a wide range of key topics impacting labs, physicians, and the healthcare space today. The presentations will offer attendees emerging details on research, findings, and outcomes.

Related Links:
Abbott